Abstract 2818: Targeting PIKfyve sensitizes gastroenteropancreatic neuroendocrine tumor to mTOR inhibition by disrupting ferritinophagy and lipid homeostasis
Yizhi Cao(Nanjing Medical University), Arul M. Chinnaiyan(Howard Hughes Medical Institute), Rahul Mannan(University of Michigan), Sarah Nicole Yee(University of Michigan), Andrej Coleski(University of Michigan), Radha Paturu(University of Michigan), Yuanyuan Qiao(University of Michigan), Yang Zheng(Harbin Medical University), Caleb Cheng(University of Michigan), Fan Yang(University of Michigan), Yitong Yin(University of Michigan), Somnath Mahapatra(University of Michigan), Shannon VanAkon(University of Michigan), Rupam Bhattacharyya(University of Michigan)
Cited by 1
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
|Cancer Discovery|2017|422
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
|Journal of Clinical Investigation|2018|209
Alitretinoin: a comprehensive review
|Expert Opinion on Investigational Drugs|2008|86
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
|Journal of Clinical Investigation|2018|53